tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Connective Tissue Diseases D003240 2 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cheilitis D002613 2 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Earache D004433 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Tongue Diseases D014060 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Nail Diseases D009260 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Venous Insufficiency D014689 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Telangiectasis D013684 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Vitiligo D014820 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Myxedema D009230 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Paresis D010291 2 associated lipids
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Mediastinitis D008480 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Shivaswamy V et al. Tacrolimus and sirolimus induce reproductive abnormalities in female rats. 2011 Transplantation pmid:21508897
McCune TR et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. 1998 Transplantation pmid:9448150
Connor A et al. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. 2012 Transplantation pmid:23318306
Plock JA et al. Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. 2015 Transplantation pmid:26102613
Stevens RB et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. 2008 Transplantation pmid:18497677
Gurk-Turner C et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. 2008 Transplantation pmid:18497682
Selzner N et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. 2009 Transplantation pmid:19935376
Rush DN et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. 2009 Transplantation pmid:19935461
Gayowski T et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. 1998 Transplantation pmid:9500623
Neylan JF Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. 1998 Transplantation pmid:9500626
Taber DJ et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. 2017 Transplantation pmid:28658199
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
D'Antiga L et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. 2002 Transplantation pmid:11792983
Gupta A et al. Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. 2009 Transplantation pmid:19696644
Shibutani S et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. 2005 Transplantation pmid:15849542
Kessler M et al. A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. 1999 Transplantation pmid:10071045
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518974
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Wasik M et al. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. 1991 Transplantation pmid:1702910
di Francesco F et al. One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. 2008 Transplantation pmid:18946356
Mahé E et al. Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. 2004 Transplantation pmid:14966435
Paramesh AS et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. 2004 Transplantation pmid:14724447
Boillot O et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. 1998 Transplantation pmid:9825815
Jain AB et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. 1998 Transplantation pmid:9825817
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. 1989 Transplantation pmid:2465593
Vossen M et al. Bone quality in swine composite tissue allografts: effects of combination immunotherapy. 2005 Transplantation pmid:16123723
Takatsuki M et al. Weaning of immunosuppression in living donor liver transplant recipients. 2001 Transplantation pmid:11502975
Poncelet AJ et al. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. 2008 Transplantation pmid:19077894
Uchida N et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. 2011 Transplantation pmid:21677598
Hariharan S Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). 2002 Transplantation pmid:12357988
Wu MJ et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. 2011 Transplantation pmid:21912349
Stempfle HU et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. 2002 Transplantation pmid:11889427
Charpentier B et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. 2003 Transplantation pmid:12660513
Jain A et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. 2011 Transplantation pmid:21378604
Gruessner RW et al. Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. 2004 Transplantation pmid:15239611
Bendahan J et al. The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. 1994 Transplantation pmid:7511255
Margreiter R et al. A double-hand transplant can be worth the effort! 2002 Transplantation pmid:12134104
Wiesner RH A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. 1998 Transplantation pmid:9734494
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Yashima J et al. Successful conversion from tacrolimus to cyclosporine after kidney transplantation. 2000 Transplant. Proc. pmid:11119895
Gibbs JF et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. 1993 Transplant. Proc. pmid:7679823
Nomoto S et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. 1994 Transplant. Proc. pmid:7513477
Siekierka JJ et al. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. 1991 Transplant. Proc. pmid:1721256
Satomura K et al. Pharmacokinetics of FK 506 in living-related liver transplantation. 1996 Transplant. Proc. pmid:8623209
Machado PG et al. Use of reduced dose of OKT3 (2.5 mg) after renal transplantation. 2002 Transplant. Proc. pmid:11959207
Zervos XA et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplant. Proc. pmid:9636568
Videla CO Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy. 2009 Jul-Aug Transplant. Proc. pmid:19715995
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Santos T et al. New Recipes With Known Ingredients: Combined Therapy of Everolimus and Low-dose Tacrolimus in De Novo Renal Allograft Recipients. 2015 Transplant. Proc. pmid:26036483
Higuchi K et al. FK506 induces the atrophy of enteric ganglia in small bowel transplantation, which can be prevented by the neuropeptide bombesin. 2006 Jul-Aug Transplant. Proc. pmid:16908293
Koyamada N et al. Strategy for chronic rejection in recipient of living-related liver transplantation. 2000 Transplant. Proc. pmid:11120102
Kaplinsky E et al. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients. 2012 Transplant. Proc. pmid:23146455
Kohnle M et al. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. 1999 Transplant. Proc. pmid:10576043
Barten MJ et al. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. 2005 Transplant. Proc. pmid:16387162
Chueh SC et al. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. 2004 Transplant. Proc. pmid:15518745
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
Meçule A et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. 2010 Transplant. Proc. pmid:20534290
Burke GW et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. 1998 Transplant. Proc. pmid:9636627
Bakar F et al. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus. 2009 Transplant. Proc. pmid:19545695
Marcén R et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. 2010 Transplant. Proc. pmid:20970609
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Villamil F et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. 2006 Transplant. Proc. pmid:17112875
Demetris AJ et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. 1993 Transplant. Proc. pmid:7505503
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Woodle ES et al. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. 1993 Transplant. Proc. pmid:7682360
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Li J et al. Regulatory effect of FK506 on CD152 and PD-1 in the liver allorecipients. 2008 Transplant. Proc. pmid:18589137
Signorell J et al. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. 2010 Transplant. Proc. pmid:21094874
Bouchta NB et al. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation. 2005 Transplant. Proc. pmid:15919485
Kumano K et al. Role of endothelin in FK 506-induced renal hypoperfusion in rats. 1995 Transplant. Proc. pmid:7533423
Green M et al. Infectious complications of pediatric liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721352
Altaca G et al. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. 2002 Transplant. Proc. pmid:12270320
Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. 2002 Transplant. Proc. pmid:12176495
Ko WJ et al. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. 1998 Transplant. Proc. pmid:9838474
Cho JH et al. Chronic rejection in pediatric liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123078
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Takayama K et al. Nonmuscle myosin heavy chain and nuclear factor-kappa B expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936372
Boots JM et al. Risk of adrenal insufficiency with steroid maintenance therapy in renal transplantation. 2002 Transplant. Proc. pmid:12176541
Klupp J et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083497
Kim JM et al. Preemptive therapy in adult liver transplant recipients in CMV-endemic area. 2010 Transplant. Proc. pmid:20430182
Alessiani M et al. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. 1997 Feb-Mar Transplant. Proc. pmid:9123483
Kimura O et al. Influence of bombesin on the intestinal mucosal immunologic response under immunosuppression. 2000 Transplant. Proc. pmid:10995942
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Navaneethan SD et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. 2006 Transplant. Proc. pmid:16797291
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
Wang CH et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. 2004 Transplant. Proc. pmid:15561257
Rabkin JM et al. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267411
McAlister VC Liposomal tacrolimus: drug migration within blood compartments. 1998 Transplant. Proc. pmid:9636404
Gotsman I et al. Effect of peripheral immune tolerance on liver-associated lymphocytes expressing NK1.1. 2000 Transplant. Proc. pmid:10856569
Blume C et al. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750357
Busque S et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. 1998 Transplant. Proc. pmid:9636507